Integer Holdings stock: growth
ITGRInteger Holdings reported $1.85B in revenue for fiscal 2025, up 7.6% on the prior year, up 11.5% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 11.5% | 8.7% | 10.6% |
| Revenue per share | 10.2% | 5.7% | 7.9% |
| Earnings | 5.9% | no data | 10.2% |
| Earnings per share | 4.7% | no data | 7.6% |
| Free cash flow | −4.1% | no data | 8.1% |
| Free cash flow per share | −5.2% | no data | 5.5% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $271.14M | $16.13M | $23.76M |
| 2007 | $318.75M | $15.05M | $22.97M |
| 2008 | $546.64M | $18.56M | $12.93M |
| 2009 | $521.82M | −$9M | $52.09M |
| 2010 | $533.43M | $33.14M | $60.75M |
| 2011 | $568.82M | $33.12M | $67.43M |
| 2012 | $646.18M | −$4.8M | $23.76M |
| 2013 | $663.95M | $36.27M | $38.2M |
| 2014 | $687.79M | $55.46M | $56.45M |
| 2015 | $800.41M | −$7.59M | −$32.14M |
| 2016 | $1.08B | $5.96M | $46.9M |
| 2017 | $1.14B | $66.68M | $102.06M |
| 2018 | $1.22B | $167.96M | $122.39M |
| 2019 | $1.26B | $96.34M | $117.16M |
| 2020 | $1.07B | $77.26M | $129.9M |
| 2021 | $1.22B | $96.81M | $103.2M |
| 2022 | $1.33B | $66.38M | $41.65M |
| 2023 | $1.56B | $90.65M | $60.28M |
| 2024 | $1.72B | $119.9M | $99.85M |
| 2025 | $1.85B | $102.76M | $105.12M |
Revenue by segment
How Integer Holdings Corporation makes its money and how that has shifted. Names are as the company reports them.
- Cardio And Vascular60%
- Cardiac Rhythm Management & Neuromodulation36%
- Other4%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2024 | 2025 | Share 2025 | |
|---|---|---|---|
| Cardio And Vascular | $949.58M | $1.11B | 60% |
| Cardiac Rhythm Management & Neuromodulation | $660.61M | $668.8M | 36.2% |
| Other | $106.41M | $70.58M | 3.8% |
| Total revenue | $1.72B | $1.85B | 100% |
Revenue by region
Where Integer Holdings Corporation generates its revenue.
- United States$979.8M53%
- Rest of world$469.9M25%
- Puerto Rico$131.3M7%
- Ireland$99.2M5%
- Other$166.4M9%
“Other” combines smaller regions with revenue the company does not assign to a region. The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| United States | $979.81M | 53.1% |
| Rest of world | $469.89M | 25.4% |
| Puerto Rico | $131.26M | 7.1% |
| Ireland | $99.16M | 5.4% |
| Other | $166.35M | 9% |
| Total revenue | $1.85B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 27 Mar 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.